Evidence map›Paper›PMID 40382685›Full record

ArticleEuropean heart journal2025

Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort.

Guillaume Baudry, Ouarda Pereira, François Roubille, Marc Villaceque, Thibaud Damy, Kévin Duarte, Philippe Tangre, Nicolas Girerd

Abstract read
In one paragraph

Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guillaume BaudryCentre d'Investigation Clinique Plurithématique 1433, Université de Lorraine, INSERM, Inserm U1116, CHRU de Nancy, 54000 Nancy, France.ORCID 0000-0002-9200-2729
Ouarda PereiraDirection Régionale du Service Médical (DRSM) Grand Est, Strasbourg, France.ORCID 0000-0001-6152-3065
François RoubillePhyMedExp, Cardiology Department, University of Montpellier, INSERM U1046, CNRS UMR, 9214, INI-CRT, Montpellier, France.ORCID 0000-0002-5288-9687
Marc VillacequeCardio Nîmes Sud, Nîmes, France.ORCID 0009-0000-3958-7572
Thibaud DamyDepartment of Cardiology, French Referral Center for Cardiac Amyloidosis, Henri Mondor University Hospital, Assistance-Publique Hôpitaux de Paris (APHP), 94000 Créteil, France.ORCID 0000-0003-4058-3848
Kévin DuarteCentre d'Investigation Clinique Plurithématique 1433, Université de Lorraine, INSERM, Inserm U1116, CHRU de Nancy, 54000 Nancy, France.ORCID 0000-0002-0292-0498
Philippe TangreDépartement des Maladies Chroniques, Caisse Nationale de l'Assurance Maladie, Paris, France.ORCID 0009-0003-9924-9075
Nicolas GirerdCentre d'Investigation Clinique Plurithématique 1433, Université de Lorraine, INSERM, Inserm U1116, CHRU de Nancy, 54000 Nancy, France.ORCID 0000-0002-3278-2057

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsOutpatient cardiology follow-up is the cornerstone of heart failure (HF) management, requiring adaptation based on patient severity. However, risk stratification using administrative data is scarce, and the association between follow-up and prognosis according to patient risk has yet to be described at a population level. This study aimed to describe prognosis and management across different strata using simple criteria, including diuretic use and prior HF hospitalization (HFH).

methodsThis nationwide cohort included all French patients reported as having HF in the previous 5 years and alive on 1 January 2020. Patients were categorized into four groups: (i) HFH within the past year (HFH ≤ 1y), (ii) HFH 1-5 years ago (HFH > 1y), (iii) not hospitalized using loop diuretics (NoHFH/LD+), and (iv) not hospitalized without loop diuretics (NoHFH/LD-). Between-group associations, all-cause mortality (ACM), and cardiology follow-up were analysed using survival models.

resultsThe study included 655 919 patients [80 years (70-87), 48% female]. One-year ACM risk was 15.9%, ranging from 8.0% (NoHFH/LD-) to 25.0% (HFH ≤ 1y). Mortality risk was 1.61-fold higher for NoHFH/LD+, 1.83-fold for HFH > 1y, and 2.32-fold for HFH ≤ 1y compared to NoHFH/LD- (P < .0001). During the first year of follow-up (2020), cardiology consultation rates were similar across groups, with 40% of patients lacking an annual visit. Compared to no consultation, a single cardiology visit in the previous year (2019) was associated with a 6%-9% absolute reduction in 1-year ACM during the following year (2020) across all groups. The number needed to consult (NNC) to prevent one modelled death was 11-16. Additional visits showed greater benefit with increasing HF severity, with NNC ranging from 55 (NoHFH/LD-) to 20 (HFH ≤ 1y). The optimal follow-up to minimize the number of deaths without increasing the total number of consultations was 1 annual visit for NoHFH/LD-, 2-3 visits for NoHFH/LD+ and HFH > 1y, and 4 visits for HFH ≤ 1y patients.

conclusionsDespite having a HF diagnosis, 40% of patients do not see a cardiologist annually, regardless of disease severity. Simple stratification based on hospitalization history and diuretic use effectively predicts outcomes. Tailoring the annual number of HF consultations according to this stratification could optimize resource use and reduce avoidable modelled deaths.

Indexed as

CardiologistsHeart FailureAgedAged, 80 and overDiureticsFemaleFollow-Up StudiesFranceHospitalizationHumansMalePrognosisRisk AssessmentSodium Potassium Chloride Symporter InhibitorsDiureticsSodium Potassium Chloride Symporter InhibitorsEpidemiologyHealthcare pathwaysHeart failureMortalityNationwideRisk stratification

Identifiers

PMID40382685
PMCPMC12349951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.